期刊文献+
共找到4篇文章
< 1 >
每页显示 20 50 100
From diagnosis to treatment of hepatocellular carcinoma: An epidemic problem for both developed and developing world 被引量:52
1
作者 Dimitrios Dimitroulis christos damaskos +12 位作者 Serena Valsami Spyridon Davakis Nikolaos Garmpis Eleftherios Spartalis Antonios Athanasiou Demetrios Moris Stratigoula Sakellariou Stylianos Kykalos Gerasimos Tsourouflis Anna Garmpi Ioanna Delladetsima Konstantinos Kontzoglou Gregory Kouraklis 《World Journal of Gastroenterology》 SCIE CAS 2017年第29期5282-5294,共13页
Hepatocellular carcinoma(HCC) is the most frequent primary liver malignancy and the third cause of cancer-related death in the Western Countries. The well-established causes of HCC are chronic liver infections such as... Hepatocellular carcinoma(HCC) is the most frequent primary liver malignancy and the third cause of cancer-related death in the Western Countries. The well-established causes of HCC are chronic liver infections such as hepatitis B virus or chronic hepatitis C virus, nonalcoholic fatty liver disease, consumption of aflatoxins and tobacco smocking. Clinical presentation varies widely; patients can be asymptomatic while symptomatology extends from right upper abdominal quadrant paint and weight loss to obstructive jaundice and lethargy. Imaging is the first key and one of the most important aspects at all stages of diagnosis, therapy and follow-up of patients with HCC. The Barcelona Clinic Liver Cancer Staging System remains the most widely classification system used for HCC management guidelines. Up until now, HCC remains a challenge to early diagnose, and treat effectively; treating management is focused on hepatic resection, orthotopic liver transplantation, ablative therapies, chemoembolization and systemic therapies with cytotocix drugs, and targeted agents. This review article describes the current evidence on epidemiology, symptomatology, diagnosis and treatment of hepatocellular carcinoma. 展开更多
关键词 HEPATOCELLULAR Cancer EPIDEMIOLOGY TREATMENT DIAGNOSIS STAGING Transplantation
下载PDF
Effects of terlipressin versus splenectomy on liver regeneration after partial hepatectomy in rats: What we know so far? 被引量:5
2
作者 antonios athanasiou eleftherios spartalis +4 位作者 mairead hennessy michael spartalis demetrios moris christos damaskos emmanouil pikoulis 《Hepatobiliary & Pancreatic Diseases International》 SCIE CAS CSCD 2018年第1期91-92,共2页
To the editor:We read with great interest the article entitled "Comparative study of the effects of terlipressin versus splenectomy on liver regeneration after partial hepatectomy in rats" by Ulmer et al.[1]... To the editor:We read with great interest the article entitled "Comparative study of the effects of terlipressin versus splenectomy on liver regeneration after partial hepatectomy in rats" by Ulmer et al.[1].The aim of this study was to analyse the impact of terlipressin ver- 展开更多
关键词 Effects of terlipressin versus splenectomy on liver regeneration after partial hepatectomy in rats What we know so far
下载PDF
Pleural involvement in cryptococcal infection
3
作者 Vasiliki E Georgakopoulou christos damaskos +2 位作者 Pagona Sklapani Nikolaos Trakas Aikaterini Gkoufa 《World Journal of Clinical Cases》 SCIE 2022年第16期5510-5514,共5页
Pleural involvement of cryptococcal infection is uncommon and is more commonly observed in immunocompromised hosts than in immunocompetent ones.Pleural involvement in cryptococcal infections can manifest with or witho... Pleural involvement of cryptococcal infection is uncommon and is more commonly observed in immunocompromised hosts than in immunocompetent ones.Pleural involvement in cryptococcal infections can manifest with or without pleural effusion.The presence of Cryptococcus spp.in the effusion or pleura is required for the diagnosis of cryptococcal pleural infection,which is commonly determined by pleural biopsy,fluid culture,and/or detection of cryptococcal antigen in the pleura or pleural fluid. 展开更多
关键词 CRYPTOCOCCOSIS Pleural effusion Pleural diseases Fungal lung diseases Pleural Cavity Cryptococcus neoformans
下载PDF
Implication of gut microbiome in immunotherapy for colorectal cancer
4
作者 Evangelos Koustas Eleni-Myrto Trifylli +8 位作者 Panagiotis Sarantis Nikolaos Papadopoulos Georgios Aloizos Ariadne Tsagarakis christos damaskos Nikolaos Garmpis Anna Garmpi Athanasios G Papavassiliou Michalis V Karamouzis 《World Journal of Gastrointestinal Oncology》 SCIE 2022年第9期1665-1674,共10页
Colorectal cancer(CRC) constitutes the third most frequently reported malignancy in the male population and the second most common in women in the last two decades. Colon carcinogenesis is a complex, multifactorial ev... Colorectal cancer(CRC) constitutes the third most frequently reported malignancy in the male population and the second most common in women in the last two decades. Colon carcinogenesis is a complex, multifactorial event, resulting from genetic and epigenetic aberrations, the impact of environmental factors, as well as the disturbance of the gut microbial ecosystem. The relationship between the intestinal microbiome and carcinogenesis was relatively undervalued in the last decade. However, its remarkable effect on metabolic and immune functions on the host has been in the spotlight as of recent years. There is a strong relationship between gut microbiome dysbiosis, bowel pathogenicity and responsiveness to anti-cancer treatment;including immunotherapy. Modifications of bacteriome consistency are closely associated with the immunologic response to immunotherapeutic agents. This condition that implies the necessity of gut microbiome manipulation. Thus, creatingan optimal response for CRC patients to immunotherapeutic agents. In this paper, we will review the current literature observing how gut microbiota influence the response of immunotherapy on CRC patients. 展开更多
关键词 Colorectal cancer Gut microbiome IMMUNOTHERAPY Checkpoint inhibitors Tumor micro-environment
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部